Literature DB >> 16323413

The CD2 family of natural killer cell receptors.

M E McNerney1, V Kumar.   

Abstract

The CD2 family of receptors is evolutionarily conserved and widely expressed on cells within the hematopoietic compartment. In recent years several new members have been identified with important roles in the immune system. CD2 family members regulate natural killer (NK) cell lytic activity and inflammatory cytokine production when engaged by ligands on tumor cells. Furthermore, a subfamily of CD2 receptors, the CD 150-like molecules, has been implicated in the pathogenesis of X-linked lymphoproliferative disease (XLP). Many of these receptors have now been shown to bind homophilically or heterophilically to other molecules within the family. With these discoveries a novel mechanism for lymphocyte regulation has emerged: CD2 family members on NK cells engage ligands on neighboring NK cells, leading to NK cell stimulation. Moreover, heterotypic stimulatory interactions between NK cells and other leukocytes also occur. In this manner, CD2 family members may provide interlymphocyte communication that maintains organization within the hematopoietic compartment and amplifies immune responses. This review discusses these multiple roles for CD2 family members, focusing specifically on the regulation of NK cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16323413     DOI: 10.1007/3-540-27743-9_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  11 in total

Review 1.  Extrinsic and intrinsic regulation of early natural killer cell development.

Authors:  Markus D Boos; Kevin Ramirez; Barbara L Kee
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

2.  Diversity of CD2 subfamily receptors in cyprinid fishes.

Authors:  Shiro Sameshima; Miki Nakao; Tomonori Somamoto
Journal:  Results Immunol       Date:  2012-02-01

3.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Expansion and diversification of the signaling capabilities of the CD2/SLAM family in Xenopodinae amphibians.

Authors:  Sergey V Guselnikov; Petr P Laktionov; Alexander M Najakshin; Konstantin O Baranov; Alexander V Taranin
Journal:  Immunogenetics       Date:  2011-06-11       Impact factor: 2.846

5.  Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells.

Authors:  Jordi Sintes; Xavier Romero; Pedro Marin; Cox Terhorst; Pablo Engel
Journal:  Exp Hematol       Date:  2008-05-20       Impact factor: 3.084

6.  CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment.

Authors:  Yanzhu Chen; Zhishang Meng; Lin Zhang; Feng Liu
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

7.  Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status.

Authors:  Preben Boysen; Ingrid Olsen; Ingvild Berg; Siri Kulberg; Grethe M Johansen; Anne K Storset
Journal:  BMC Immunol       Date:  2006-04-27       Impact factor: 3.615

Review 8.  Cell biological steps and checkpoints in accessing NK cell cytotoxicity.

Authors:  Emily M Mace; Prachi Dongre; Hsiang-Ting Hsu; Papiya Sinha; Ashley M James; Shaina S Mann; Lisa R Forbes; Levi B Watkin; Jordan S Orange
Journal:  Immunol Cell Biol       Date:  2014-01-21       Impact factor: 5.126

9.  CD2 promotes human natural killer cell membrane nanotube formation.

Authors:  Colin J Comerci; Emily M Mace; Pinaki P Banerjee; Jordan S Orange
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity.

Authors:  Markus D Boos; Yoshifumi Yokota; Gerard Eberl; Barbara L Kee
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.